| 88 | 1 | 54 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：探讨胰腺导管腺癌患者肿瘤组织中组织激肽释放酶11(KLK11)的表达水平及临床意义。方法：选取2018年1月—2022年12月在宜昌市中心人民医院接受根治性胰十二指肠切除术的152例胰腺导管腺癌患者，收集所有纳入患者的临床资料，分析KLK11低表达(n=65)和高表达(n=87)的免疫组化结果及其对患者生存的影响，并进一步通过Cox比例风险模型进行单因素和多因素分析探讨影响胰腺导管腺癌患者生存的独立影响因素。结果：免疫组化结果显示，胰腺导管腺癌组织中存在KLK11低表达及高表达；KLK11高表达组患者的生存率明显低于KLK11低表达组患者(P=0.003);肿瘤中-低分化(HR=3.447,95%CI:1.542,7.707)、肿瘤>3.0 cm(HR=4.452,95%CI:2.094,9.465)、TNM分期为Ⅱ期(HR=14.840,95%CI:5.284,41.680)/Ⅲ期(HR=27.880,95%CI:9.419,82.550)、有门静脉侵犯(HR=4.929,95%CI:1.395,17.421)及KLK11高表达(HR=6.007,95%CI:2.270,15.895)均是影响胰腺导管腺癌患者术后生存的独立危险因素(均P<0.05)。结论：肿瘤中-低分化、肿瘤>3.0 cm、TNM分期为Ⅱ期/Ⅲ期、有门静脉侵犯及KLK11高表达是影响胰腺导管腺癌患者术后生存的独立危险因素。
Abstract：Objective: To investigate the expression level and clinical significance of kallikrein 11(KLK11) in tumor tissue of patients with pancreatic ductal adenocarcinoma. Methods: A total of 152 patients with pancreatic ductal adenocarcinoma who underwent radical pancreatoduodenectomy at Yichang Central People's Hospital from January 2018 to December 2022 were selected. The clinical data of all included patients were collected, and the immunohistochemical results of low expression(n=65) and high expression(n=87) of KLK11 were analyzed, as well as their impact on the survival of patients. Furthermore, univariate and multivariate analyses were conducted using the Cox proportional hazards model to explore the independent influencing factors affecting the survival of patients with pancreatic ductal adenocarcinoma. Results: Immunohistochemical results showed that there were low and high expressions of KLK11 in pancreatic ductal adenocarcinoma tissues. The survival rate of patients with high KLK11 expression was significantly lower than that of patients with low KLK11 expression(P=0.003). Moderate-to-poor tumor differentiation(HR=3.447, 95%CI: 1.542, 7.707), tumor size >3.0 cm(HR=4.452, 95%CI: 2.094, 9.465), TNM stage Ⅱ(HR=14.840, 95%CI: 5.284, 41.680)/Ⅲ(HR=27.880, 95%CI: 9.419, 82.550), portal vein invasion(HR=4.929, 95%CI: 1.395, 17.421), and high KLK11 expression(HR=6.007, 95%CI: 2.270, 15.895) were independent risk factors affecting the survival of patients with pancreatic ductal adenocarcinoma after surgery(all P<0.05). Conclusion: Moderate-to-poor tumor differentiation, tumor size >3.0 cm, TNM stage Ⅱ/Ⅲ, portal vein invasion, and high KLK11 expression are independent risk factors affecting the survival of patients with pancreatic ductal adenocarcinoma after surgery.
[1] Halbrook C J,Lyssiotis C A,Pasca di Magliano M,et al.Pancreatic cancer:advances and challenges[J].Cell,2023,186(8):1729-1754.
[2] Duan H Y,Li L,He S M.Advances and prospects in the treatment of pancreatic cancer[J].Int J Nanomedicine,2023,18:3973-3988.
[3] Tao J X,Yang G,Zhou W C,et al.Targeting hypoxic tumor microenvironment in pancreatic cancer[J].J Hematol Oncol,2021,14(1):1-25.
[4] Prassas I,Eissa A,Poda G,et al.Unleashing the therapeutic potential of human kallikrein-related serine proteases[J].Nat Rev Drug Discov,2015,14(3):183-202.
[5] Zhou S Q,Liu S Y,Tian G,et al.KLK5 is associated with the radioresistance,aggression,and progression of cervical cancer[J].Gynecol Oncol,2022,166(1):138-147.
[6] Riedel M,Bronger H,Magdolen V,et al.The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer[J].Expert Rev Mol Diagn,2021,21(6):535-545.
[7] Candido J B,Maiques O,Boxberg M,et al.Kallikrein-related peptidase 6 is associated with the tumour microenvironment of pancreatic ductal adenocarcinoma[J].Cancers,2021,13(16):3969.
[8] Li X L,Bi H L,Yuan T J,et al.Diagnostic and prognostic values of KLK11 in nasopharyngeal carcinoma[J].Eur Rev Med Pharmacol Sci,2020,24(18):9423-9428.
[9] Zhao R M,Wang S Y,Liu J S,et al.KLK11 acts as a tumor-inhibitor in laryngeal squamous cell carcinoma through the inactivation of Akt/Wnt/β-catenin signaling[J].J Bioenerg Biomembr,2021,53(1):85-96.
[10] Srinivasan S,Kryza T,Batra J,et al.Remodelling of the tumour microenvironment by the kallikrein-related peptidases[J].Nat Rev Cancer,2022,22(4):223-238.
[11] Xiang F Y,Wang Y Q,Cao C Y,et al.The role of kallikrein 7 in tumorigenesis[J].Curr Med Chem,2022,29(15):2617-2631.
[12] Siriphak S,Chanakankun R,Proungvitaya T,et al.Kallikrein-11,in association with coiled-coil domain containing 25,as a potential prognostic marker for cholangiocarcinoma with lymph node metastasis[J].Molecules,2021,26(11):3105.
[13] Ozturk T,Kain E Z,Tuzuner M B,et al.Kallikrein 11 down-regulation in breast carcinoma:correlation with prognostic parameters[J].In Vivo,2021,35(6):3233-3243.
[14] Mukama T,Fortner R T,Katzke V,et al.Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer[J].Br J Cancer,2022,126(9):1301-1309.
[15] He X,Meng F,Qin L Y,et al.KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma[J].Am J Cancer Res,2019,9(10):2264-2277.
[16] Liu Y Y,Gong W W,Preis S,et al.A pair of prognostic biomarkers in triple-negative breast cancer:KLK10 and KLK11 mRNA expression[J].Life (Basel),2022,12(10):1517.
[17] Dorn J,Bayani J,Yousef G M,et al.Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies[J].Thromb Haemost,2013,110(3):408-422.
[18] Ding Y,Wang Z H,Chen C,et al.MiR-1304 targets KLK11 to regulate gastric cancer cell proliferation through the mTOR signaling pathway[J].Carcinogenesis,2023:bgad077.
[19] Fulghieri P,Stivala L A,Sottile V.Modulating cell differentiation in cancer models[J].Biochem Soc Trans,2021,49(4):1803-1816.
[20] Liu Y P,Zheng C C,Huang Y N,et al.Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment[J].MedComm (2020),2021,2(3):315-340.
[21] Zhang Q,Li B S,Zhang S Y,et al.Prognostic impact of tumor size on patients with metastatic colorectal cancer:a large SEER-based retrospective cohort study[J].Updates Surg,2023,75(5):1135-1147.
[22] Alese O B,Zhou W,Jiang R J,et al.Predictive and prognostic effects of primary tumor size on colorectal cancer survival[J].Front Oncol,2021,11:728076.
[23] Liang Y X,Cui J L,Ding F H,et al.A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma[J].iScience,2023,26(9):107 589.
[24] Zhou L,Wang J,Zhang X X,et al.Prognostic value of preoperative NLR and vascular reconstructive technology in patients with pancreatic cancer of portal system invasion:a real world study[J].Front Oncol,2021,11:682928.
[25] de Visser K E,Joyce J A.The evolving tumor microenvironment:from cancer initiation to metastatic outgrowth[J].Cancer Cell,2023,41(3):374-403.
[26] Yang J,Liu Y,Liu S.The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion[J].Cell Death Dis,2023,14(8):506.
[27] Stuardo-Parada A,López-Muňoz R,Villarroel-Espindola F,et al.Minireview:functional roles of tissue kallikrein,kinins,and kallikrein-related peptidases in lung cancer[J].Med Oncol,2023,40(8):224.
[28] Carino A,Graziosi L,Marchianò S,et al.Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential[J].Front Oncol,2021,11:663771.
[29] Xu Z B,Chi P,Pan J,et al.Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer[J].Exp Ther Med,2016,12(5):2855-2860.
[30] Goettig P,Magdolen V,Brandstetter H.Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs)[J].Biochimie,2010,92(11):1546-1567.
[31] Wolf W C,Evans D M,Chao L,et al.A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness[J].Am J Pathol,2001,159(5):1797-1805.
[32] Shariff L,Zhu Y N,Cowper B,et al.Sunflower trypsin inhibitor (SFTI-1) analogues of synthetic and biological origin via N→S acyl transfer:potential inhibitors of human Kallikrein-5 (KLK5)[J].Tetrahedron,2014,70(42):7675-7680.
[33] De Vita E,Schüler P,Lovell S,et al.Depsipeptides featuring a neutral P1 are potent inhibitors of kallikrein-related peptidase 6 with on-target cellular activity[J].J Med Chem,2018,61(19):8859-8874.
[34] Lee K Y,Chau C H,Price D K,et al.Drugging the undruggable:activity-based protein profiling offers opportunities for targeting the KLK activome[J].Cancer Biol Ther,2022,23(1):136-138.
[35] Sotiropoulou G,Zingkou E,Pampalakis G.Novel specific activity-based probes validate KLK proteases as druggable targets[J].Cancer Biol Ther,2022,23(1):401-403.
基本信息:
中图分类号:R735.9
引用信息:
[1]姚汝铖,胡军,郑军.胰腺导管腺癌患者KLK11的表达水平及患者生存的影响因素分析[J].巴楚医学,2024,7(02):92-97.
基金信息:
湖北省卫生健康委员会科研项目(No:WJ2021M067,WJ2021M065); 宜昌市医疗卫生研究项目(No:A21-2-024,A22-2-015,A22-2-008)
2024-06-28
2024-06-28